Anthrax is an acute infectious disease caused by the spore-forming bacterium Bacillus anthracis. Anthrax most commonly occurs in wild and domestic lower vertebrates (cattle, sheep, goats, camels, antelopes, and other herbivores), but it can also occur in humans when they are exposed to infected animals or tissue from infected animals.
Anthrax is most common in agricultural regions where it occurs in animals. These include South and Central America, Southern and Eastern Europe, Asia, Africa, the Caribbean, and the Middle East. When anthrax affects humans, it is usually due to an occupational exposure to infected animals or their products. Workers who are exposed to dead animals and animal products from other countries where anthrax is more common may become infected with B. anthracis (industrial anthrax). Anthrax outbreaks occur in the United States on an annual basis in livestock and wild game animals such as deer.
Anthrax infection can occur in three forms: cutaneous (skin), inhalation, and gastrointestinal. B. anthracis spores can live in the soil for many years, and humans can become infected with anthrax by handling products from infected animals or by inhaling anthrax spores from contaminated animal products. Anthrax can also be spread by eating undercooked meat from infected animals. It is rare to find infected animals in the United States.
Federal government labs in Atlanta were temporarily shut after it was discovered they had improperly sent potentially deadly pathogens, including anthrax, botulism and virulent bird flue virus, to other labs.
Today's headlines include coverage of Medicare, the health law and veterans' care policy issues as well as reports from the campaign trail.
The Department of Health and Human Services released a report Friday declaring that 76 million Americans with private insurance became eligible for more preventive services with no out-of-pocket fees as a result of the 2010 healthcare law, the Patient Protection and Affordable Care Act (a.k.a. Obamacare). Because Democrats are counting on female voters to help them at the polls in November, the report highlighted how women had been helped by that aspect of Obamacare.
A Unanimous Supreme Court: Abortion Rights Lose A Buffer
Yet on Thursday the Supreme Court, in McCullen v. Coakley, struck down that law for violating the First Amendment.
Aradigm Corporation ("Aradigm" or the "Company") today announced the dosing of the first patient in the ORBIT-4 (Once-daily Respiratory Bronchiectasis Inhalation Treatment) Phase III pivotal clinical trial of Aradigm's proprietary formulation of inhaled ciprofloxacin (Pulmaquin®) for the treatment of non-cystic fibrosis bronchiectasis (non-CF BE).
Today's early morning highlights from the major news organizations, including reports about a new poll of showing a majority of those signing up for marketplace plans had been uninsured before and the Obama administration's decision to extend marriage benefits, including family leave, to same-sex couples.
PaxVax Inc., a specialty vaccine company with a commercial focus on travel and biodefense and a social mission to ensure global access to its vaccines, today announced that it has entered into a research and development collaboration with the University of California, San Diego to develop a combination vaccine to prevent genital herpes simplex virus (HSV) infections.
Decades of neglect have allowed infectious diseases to devastate the lives of thousands of people in the developing world, a study reveals.
Aradigm Corporation is pleased to announce that its common shares have been approved for listing on the NASDAQ Capital Market.
Aradigm Corporation (the "Company") today announced that the U.S. Food and Drug Administration (FDA) has designated the Company's lead inhaled antibiotic candidate, Pulmaquin®, as a Qualified Infectious Disease Product (QIDP).
Aradigm Corporation today announced financial results for the first quarter and three months ended March 31, 2014.
Air and surface sampling techniques currently used by the US government are effective in fighting bioterrorism and potentially saving lives, a Saint Louis University researcher finds.
Emergent BioSolutions Inc. announced today that the U.S. Food and Drug Administration has granted Orphan Drug Designation to BioThrax (Anthrax Vaccine Adsorbed) for post-exposure prophylaxis (PEP) of anthrax disease resulting from suspected or confirmed exposure to Bacillus anthracis.
A credit-card-sized anthrax detection cartridge developed at Sandia National Laboratories and recently licensed to a small business makes testing safer, easier, faster and cheaper.
Aradigm Corporation (the "Company") today announced financial results for the fourth quarter and full year ended December 31, 2013.
A disease-causing bacterium found in the mouth needs manganese, a trace mineral, in order to cause a serious heart infection, according to a preclinical study led by researchers at Virginia Commonwealth University Philips Institute for Oral Health Research in the School of Dentistry.
Shortly following the 9/11 terror attack in 2001, letters containing anthrax spores were mailed to news outlets and government buildings killing five people and infecting 17 others.
Bacteria have developed many different ways of smuggling their toxic cargo into cells. Tripartite Tc toxin complexes, which are used by bacteria like the plague pathogen Yersinia pestis and the insect pathogen Photorhabdus luminescens, are particularly unusual.
Tularemia, aka "rabbit fever," is endemic in the northeastern United States, and is considered to be a significant risk to biosecurity -- much like anthrax or smallpox -- because it has already been weaponized in various regions of the world.
Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that the National Institute of Allergy and Infectious Diseases has awarded Soligenix a Small Business Innovation Research grant to support further preclinical development of SGX943 as a treatment for melioidosis.